Dataset Information

Prognostic value of high-sensitivity cardiac troponin I early after coronary artery bypass graft surgery

ABSTRACT:

Background

The diagnosis of periprocedural myocardial infarction (PMI) after coronary artery bypass graft (CABG) is based on biochemical markers along with clinical and instrumental findings. However, there is not a clear cutoff value of high-sensitivity cardiac troponin (hs-cTn) to identify PMI. We hypothesized that isolated hs-cTn concentrations in the first 24 h following CABG could predict cardiac adverse events (in-hospital death and PMI) and/or left ventricular ejection fraction (LVEF) decrease.

Methods

We retrospectively enrolled all consecutive adult patients undergoing CABG, alone or in association with other cardiac surgery procedures, over 1 year. Hs-cTn I concentrations (Access, Beckman Coulter) were serially measured in the post-operative period and analyzed according to post-operative outcomes.

Results

300 patients were enrolled; 71.3% underwent CABG alone, 33.7% for acute coronary syndrome. Most patients showed hs-cTn I values superior to the limit required by the latest guidelines for the diagnosis of PMI. Five patients (1.7%) died, 8% developed a PMI, 10.6% showed a LVEF decrease ≥ 10%. Hs-cTn I concentrations did not significantly differ with respect to death and/or PMI whereas they were associated with LVEF decrease ≥ 10% (p value < 0.005 at any time interval), in particular hs-cTn I values at 9–12 h post-operatively. A hs-cTn I cutoff of 5556 ng/L, a value 281 (for males) and 479 (for females) times higher than the URL, at 9–12 h post-operatively was identified, representing the best balance between sensitivity (55%) and specificity (79%) in predicting LVEF decrease ≥ 10%.

Conclusions

Hs-cTn I at 9–12 h post-CABG may be useful to early identify patients at risk for LVEF decrease and to guide early investigation and management of possible post-operative complications.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13019-022-02027-x.

SUBMITTER: Nanni S

PROVIDER: S-EPMC9628166 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Background and objectiveCoronary artery bypass grafting (CABG) is an effective treatment for coronary artery disease, high risk of complications, making it particularly important to assess patient prognosis. High-sensitivity cardiac troponin (hs-cTn), as a key biomarker of myocardial injury, plays an important role in evaluating the prognosis of patients after CABG. However, the optimal threshold values for hs-cTn in the current guidelines are all artificially set, lacking a unified standard. This narrative review aims to fill the knowledge gap and provide new directions for future research. This is of significant importance for optimizing the management of patients after CABG, improving prognosis, and for developing more precise and personalized treatment strategies.MethodsWe conducted a structured search on PubMed, Web of Science MEDLINE and Cochrane Library using terms like "High-Sensitivity Cardiac Troponin", "Coronary Artery Bypass Grafting", "Prognosis", "Mortality", and "Postoperative Outcomes" to identify English-language studies from inception to 25 July 2024. This article systematically reviews recent studies on hs-cTn levels and prognostic risk factors after CABG, aiming to comprehensively sort out and analyze existing research findings.Key content and findingsStudies show that the release of hs-cTnT and hs-cTnI is related to postoperative myocardial injury/infarction and short-term mortality, but there is still controversy in the conclusions regarding long-term mortality. In addition, different studies have drawn different conclusions about the application of hs-cTnI in postoperative myocardial infarction, restenosis, and hypoxemia, as well as its association with mortality. However, a common view is that the hs-cTn cutoff values used in current clinical practice are too conservative, which may limit the accuracy of its prognosis assessment.ConclusionsHs-cTn has significant value in the prognosis assessment of patients after CABG, but its clinical decision level often exceeds the critical values specified in the guidelines. In the future, more rigorous prospective multicenter trials need to be conducted in different populations to further determine the optimal diagnostic thresholds for hs-cTn, thereby improving the accuracy of prognosis assessment in patients after CABG.

Project description:BackgroundWhile coronary artery bypass grafting (CABG) surgery is effective in reducing the risk of myocardial infarction and subsequent cardiac events by improving myocardial perfusion, the risk of sudden cardiac death (SCD) remains notable.MethodsThis retrospective observational study evaluated the efficacy of dual antiplatelet therapy (DAPT) in preventing sudden cardiac death (SCD) among patients undergoing CABG surgery at a major U.S. cardiac center (2012-2015). Data was manually extracted from electronic medical records between 23/04/2017 to 30/03/ 2018 and verified for accuracy, with patients categorized into DAPT or aspirin monotherapy groups based on discharge prescriptions.ResultsOf 2,476 patients followed in this post-CABG study, the analysis included 1,005 patients who received aspirin monotherapy (AMT) and 1,458 patients who received dual antiplatelet therapy (DAPT). AMT group had a significantly higher incidence of SCD compared to those on DAPT (3.1% vs 0.8%; OR = 3.831, 95% CI: 1.961-7.519; p < 0.001). The binary regression model indicated that a higher BMI was associated with an increased risk of SCD (HR = 1.064, 95% CI: 1.012-1.118, p = 0.014). However, patients prescribed P2Y12 antagonists (HR = 0.285, 95% CI: 0.135-0.603, p < 0.001), those with a GFR > 60 ml/min (HR = 0.314, 95% CI: 0.158-0.624, p < 0.001), and those with a higher ejection fraction (HR = 0.962, 95% CI: 0.939-0.986, p = 0.002) were less likely to experience SCD following CABG. A 1 kg/m2 increase in BMI is associated with a 6.4% increase in the risk of SCD. Morbidly obese patients with BMI > 35 were more likely to have experienced SCD than those with BMI < 35 (HR = 2.400, 95% CI: 1.204-4,787; p = 0.013). Similarly, patients with EF > 40% had decreased incidence of SCD compared to those with EF < 40% (HR 0.347, 95% CI:0.158-0.763; p = 0.008). Patients on AMT had higher all-cause (OR = 2.136, 95% CI 1.502-3.038; p < 0.001) and CV mortality (OR = 3.731, 95% CI 2.233-6.235; p < 0.001) but had lower incidence of major bleeding (by drop in hemoglobin criteria) (OR = 0.704, 95% CI: 0.595-0.833; p < 0.001) compared to the DAPT group.ConclusionDAPT prescription after CABG improves survival and lowers risk of sudden cardiac death.